Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
From policy advisors who resigned in protest to an agency trying to settle a patent dispute, many of the newsmakers in our 2017 Yearbook made notable decisions.
From a worldwide march in favor of science to an increased focus on diversity and gender equality in the workplace, 2017 was a year that was dominated by activism and social causes. Amidst these events, however, were concerns over unproven treatments and emergency funding.
In 2017, cancer drugs once again dominated the news, with many of these medications making headlines for being the first of their kind to gain approval. Beyond cancer, drugs for inflammatory diseases also received attention, for both their successes and their failures.
This past year included numerous research studies that broke the mold and elucidated new biology and drug targets. Here are some of the exciting papers from 2017 that moved biomedicine forward.